Lomangino, K. (2017) 'Not statistically significant but clinically meaningful': A researcher calls 'BS' on cancer drug spin, Health News Review (published online 24 March 2017) bit.ly/35riDTq

Oyedele, A. (2014) 19 of the Most Expensive Substances In the World, Business Insider (published online 22 September 2014) bit.ly/36kqx1W

Kim, C. and Prasad, V. (2015) Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals, JAMA Intern Med. 175: 1992–4 doi:10.1001/jamainternmed.2015.5868

Prasad, V., McCabe, C. and Mailankody, S. (2018) Low-value approvals and high prices might incentivize ineffective drug development, Nat Rev Clin Oncol 15: 399–400 doi:10.1038/ s41571–018–0030–2

Prasad, V. and Mailankody, S. (2017) Research and development spending to bring a single cancer drug to market and revenues after approval, JAMA Intern Med. 177: 1569–1575 doi:10.1001/jamainternmed.2017.3601

Prasad, V. (2016) Perspective: The precision-oncology illusion, Nature 537: S63 doi:10.1038/537S63a

Perelson, A.S., Neumann, A.U., Markowitz, M. et al (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time, Science 271: 1582–6 doi:10.1126/science.271.5255.1582

The Antiretroviral Therapy Cohort Collaboration (2017) Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies, The Lancet HIV 4: PE349-E356 doi:10.1016/ S2352–3018(17)30066–8

Clarke, P.A., Roe, T., Swabey, K. et al. (2019) Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer, Oncogene 38: 5076–5090 doi:10.1038/s41388–019–0780-z

Behan, F.M., Iorio, F., Picco, G. et al. (2019) Prioritization of cancer therapeutic targets using CRISPR – Cas9 screens, Nature 568: 511–516 doi:10.1038/s41586–019–1103–9